The national cost of managing genital warts (GWs) in the UK has not been fully estimated,
yet is required to inform decisions on vaccination against human papillomavirus. This study …

Objectives To estimate the total number of cases of, and cost of care for, genital warts (GWs)
in England, to inform economic evaluations of human papillomavirus vaccination. Methods …

Objectives To estimate for the first time the incidence and healthcare resource utilisation
associated with genital warts (GW) in Australia prior to the human papillomavirus …

Genital warts, 90% of which are caused by human papillomavirus types 6 and 11, are a
significant problem in the UK. The cost of managing genital warts was previously estimated …

Objectives To estimate the loss of quality of life and cost of treatment associated with genital
warts seen in sexual health clinics. Methods A cross-sectional questionnaire study and case …

Background: Data on the burden of genital warts in terms of treatment costs and detriment to
quality of life (QoL) are required to assess cost-effectiveness of quadrivalent human …

Objectives: To determine the average cost of a case of genital warts, for both males and
females, with a view to informing the current debate as to which Human papillomavirus …

Objectives To estimate the prevalence of, and describe risk factors for, genital warts (GWs) in
the British population, following the introduction of the bivalent (human papillomavirus (HPV) …

Genital warts (GWs) caused by the human papilloma virus (HPV) are a significant health
problem due to high prevalence and rate of recurrence. Bivalent vaccine has been used …

Abstract Background In Italy the prevalence of genital warts in women (15–64 years) is
approximately 0.6% with an incidence of 0.4% per year. Treatments for GW are usually long …